Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors

Guenat,David; Deroo,Olivier; Magnin,Sandrine; Chaigneau,Loïc; Monnien,Franck; Borg,Christophe; Mougin,Christiane; Emile,Jean-François; Prétet,Jean-Luc

doi:10.3892/or.2017.5384

Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors

Authors:
- David Guenat
- Olivier Deroo
- Sandrine Magnin
- Loïc Chaigneau
- Franck Monnien
- Christophe Borg
- Christiane Mougin
- Jean-François Emile
- Jean-Luc Prétet
View Affiliations

Affiliations: CHRU Besançon, Besançon, France, Université Versailles, Boulogne, France
Published online on: January 17, 2017 https://doi.org/10.3892/or.2017.5384
Pages: 1671-1681

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors distinguished by driver mutations in proto-oncogenes KIT or PDGFRA in 85-90% of cases. These mutations have been linked to the response to imatinib, a multikinase inhibitor, and have independent prognostic impact. Here, we describe the prospective study of the molecular characteristics of 104 GISTs from French adult patients analyzed routinely through the National Hospital Program of Molecular Cancer Diagnosis. All patients with GISTs diagnosed at the University Hospital of Besançon between August 2005 and October 2014 were prospectively included in the present study. KIT, PDGFRA and KRAS-codons 12 and 13 as well as BRAF codon 600 mutations were analyzed by Sanger sequencing or SNaPshot. KIT and PDGFRA mutations were detected in 71.2 and 19.2% of the cases, respectively. A total of 43 different mutations were detected of which 13 had never been described. As expected, KIT exon 9 and PDGFRA exon 18 mutations were associated with small bowel and gastric localizations respectively. No mutation was found in KRAS and BRAF. Molecular studies are critical to improve the management of GISTs. Our study enhances the current knowledge by describing 13 new mutations in KIT. A common molecular pattern in all KIT exon 11 substitutions is also described for the first time in this study but its significance remains unknown since genetic and environmental risk factors favoring the development of GISTs such as DNA repair defects and exposure to carcinogens are not currently known.

View Figures

View References

1	Corless CL, Barnett CM and Heinrich MC: Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer. 11:865–878. 2011.PubMed/NCBI
2	Joensuu H, Hohenberger P and Corless CL: Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013. View Article : Google Scholar : PubMed/NCBI
3	Monges G, Bisot-Locard S, Blay JY, Bouvier AM, Urbieta M, Coindre JM and Scoazec JY: The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists. Bull Cancer. 97:E16–E22. 2010.PubMed/NCBI
4	Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, et al: Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 29:1765–1772. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sarlomo-Rikala M, Kovatich AJ, Barusevicius A and Miettinen M: CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 11:728–734. 1998.PubMed/NCBI
6	Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
7	Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y: Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology. 125:660–667. 2003. View Article : Google Scholar : PubMed/NCBI
9	Nannini M, Biasco G, Astolfi A and Pantaleo MA: An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet. 50:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
10	Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A and Bihl MP: V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 62:613–616. 2009. View Article : Google Scholar : PubMed/NCBI
11	Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P and Antonescu CR: Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 47:853–859. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY and Coindre JM: BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 133:141–148. 2010. View Article : Google Scholar : PubMed/NCBI
13	Miettinen M, Killian JK, Wang Z-F, Lasota J, Lau C, Jones L, Walker R, Pineda M, Zhu YJ, Kim SY, et al: Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 37:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jones DH, Caracciolo JT, Hodul PJ, Strosberg JR, Coppola D and Bui MM: Familial gastrointestinal stromal tumor syndrome: Report of 2 cases with KIT exon 11 mutation. Cancer Control. 22:102–108. 2015.PubMed/NCBI
15	Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, et al: NIH Pediatric and Wild-Type GIST Clinic: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 108:314–318. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C, Casadio R, et al: GIST Study Group: Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum Genet. 22:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
17	Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, et al: Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. Lancet Oncol. 13:265–274. 2012. View Article : Google Scholar : PubMed/NCBI
18	Bischof DA, Kim Y, Dodson R, Jimenez MC, Behman R, Cocieru A, Fisher SB, Groeschl RT, MH III Squires, Maithel SK, et al: Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: A multi-institutional analysis of 502 patients. JAMA Surg. 150:299–306. 2015. View Article : Google Scholar : PubMed/NCBI
19	Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
20	Miettinen M and Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, et al: Polish Clinical GIST Registry: Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol. 23:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC and Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 279:31655–31663. 2004. View Article : Google Scholar : PubMed/NCBI
23	Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene. 20:5054–5058. 2001. View Article : Google Scholar : PubMed/NCBI
24	Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:925–932. 2000.PubMed/NCBI
25	Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
26	Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, van den Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
27	Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 26:5352–5359. 2008. View Article : Google Scholar : PubMed/NCBI
28	Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, et al: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64:5913–5919. 2004. View Article : Google Scholar : PubMed/NCBI
29	Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner CC, Heinicke T and Hohenberger P: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 6:249–251. 2005. View Article : Google Scholar : PubMed/NCBI
31	Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL and Fletcher JA: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 216:64–74. 2008. View Article : Google Scholar : PubMed/NCBI
32	Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T and Hirota S: Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 99:799–804. 2008. View Article : Google Scholar : PubMed/NCBI
33	Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 368:1329–1338. 2006. View Article : Google Scholar : PubMed/NCBI
34	George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, et al: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J Clin Oncol. 30:2401–2407. 2012. View Article : Google Scholar : PubMed/NCBI
35	Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, et al: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 13:4874–4881. 2007. View Article : Google Scholar : PubMed/NCBI
36	Cullinane C, Natoli A, Hui Y, Conus N, Jackson S, Brüggen J, Manley PW and McArthur GA: Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther. 9:1461–1468. 2010. View Article : Google Scholar : PubMed/NCBI
37	Steigen SE, Eide TJ, Wasag B, Lasota J and Miettinen M: Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS. 115:289–298. 2007. View Article : Google Scholar : PubMed/NCBI
38	Mazzola P, Spitale A, Banfi S, Mazzucchelli L, Frattini M and Bordoni A: Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): A population-based study in the South of Switzerland, 1999–2005. Histol Histopathol. 23:1379–1386. 2008.PubMed/NCBI
39	Nowak F, Soria JC and Calvo F: Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol. 9:479–486. 2012. View Article : Google Scholar : PubMed/NCBI
40	Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S and Madden TL: Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 13:1342012. View Article : Google Scholar : PubMed/NCBI
41	Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, Mougin C, Bigand M, Girardo B, Borg C, et al: A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J Mol Diagn. 13:485–492. 2011. View Article : Google Scholar : PubMed/NCBI
42	Cassier PA, Ducimetière F, Lurkin A, Ranchère-Vince D, Scoazec JY, Bringuier PP, Decouvelaere AV, Méeus P, Cellier D, Blay JY, et al: A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône A lpes region: Incidence and molecular distribution of GIST in a European region. Br J Cancer. 103:165–170. 2010. View Article : Google Scholar : PubMed/NCBI
43	Mendoza Y, Singh C, Mewa J Castillo, Fonseca E, Smith R and Pascale JM: Beginning of personalized medicine in Panama: Molecular and pathological characteristics of gastrointestinal stromal tumors from archival paraffin-embedded tissue. Oncol Lett. 2:941–947. 2011.PubMed/NCBI
44	Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, et al: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 26:5360–5367. 2008. View Article : Google Scholar : PubMed/NCBI
45	Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, van Glabbeke M, Verweij J, Blay JY; Hogendoorn PCEORTC Soft Tissue and Bone Sarcoma Group, ; et al: Australasian Trials Group: Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer. 44:1855–1860. 2008. View Article : Google Scholar : PubMed/NCBI
46	Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, et al: Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol. 51:528–536. 2012. View Article : Google Scholar : PubMed/NCBI
47	Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, et al: KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 33:634–642. 2015. View Article : Google Scholar : PubMed/NCBI
48	Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, et al: Liguria GIST Unit: Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer. 16:596–601. 2013. View Article : Google Scholar : PubMed/NCBI
49	Ahmad F, Lad P, Bhatia S and Das BR: Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: Determination of frequency, distribution pattern and identification of novel mutations in Indian patients. Med Oncol. 32:4242015. View Article : Google Scholar : PubMed/NCBI
50	Wang M, Xu J, Zhao W, Tu L, Qiu W, Wang C, Shen Y, Liu Q and Cao H: Prognostic value of mutational characteristics in gastrointestinal stromal tumors: A single-center experience in 275 cases. Med Oncol. 31:8192014. View Article : Google Scholar : PubMed/NCBI
51	Minárik G, Plank L, Lasabová Z, Szemes T, Burjanivová T, Szépe P, Buzalková V, Porubský D and Sufliarsky J: Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia. APMIS. 121:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
52	Tryggvason G, Hilmarsdottir B, Gunnarsson GH, Jónsson JJ, Jónasson JG and Magnússon MK: Tyrosine kinase mutations in gastrointestinal stromal tumors in a nation-wide study in Iceland. APMIS. 118:648–656. 2010. View Article : Google Scholar : PubMed/NCBI
53	Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008. View Article : Google Scholar : PubMed/NCBI
54	Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
55	Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P and Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3:655–664. 2002. View Article : Google Scholar : PubMed/NCBI
56	Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST), . Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol. 28:1247–1253. 2010. View Article : Google Scholar : PubMed/NCBI
57	Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R and Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 106:887–895. 2003. View Article : Google Scholar : PubMed/NCBI
58	Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG and Nilsson B: Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 130:1573–1581. 2006. View Article : Google Scholar : PubMed/NCBI
59	O'Brien KM, Orlow I, Antonescu CR, Ballman K, McCall L, DeMatteo R and Engel LS: Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS One. 8:e621192013. View Article : Google Scholar : PubMed/NCBI
60	He HY, Fang WG, Zhong HH, Li Y, Zheng J, Du J, Heng WJ and Wu BQ: Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST). Zhonghua Bing Li Xue Za Zhi. 35:262–266. 2006.(In Chinese). PubMed/NCBI
61	Baker G, Babb C, Schnugh D, Nayler S, Louw M, Goedhals J, Bringuier PP, Blay JY and Willem P: Molecular characterisation of gastrointestinal stromal tumours in a South African population. Oncol Lett. 5:155–160. 2013.PubMed/NCBI
62	Saito K, Sakurai S, Sano T, Sakamoto K, Asao T, Hosoya Y, Nakajima T and Kuwano H: Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy. Cancer Sci. 99:253–259. 2008. View Article : Google Scholar : PubMed/NCBI